Anzeige
Mehr »
Login
Freitag, 31.01.2025 Börsentäglich über 12.000 News von 685 internationalen Medien
Gold-Rally Richtung 3.000 $: Der brasilianische Gold-Play, das Sie kennen sollten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40EDR | ISIN: US46489V3024 | Ticker-Symbol: AAJ0
Tradegate
30.01.25
08:00 Uhr
3,540 Euro
-0,120
-3,28 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PERSPECTIVE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PERSPECTIVE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,5403,78030.01.
3,5803,72030.01.

Aktuelle News zur PERSPECTIVE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
24.01.Perspective Therapeutics Touts Encouraging Updated Data From Gastrointestinal Cancer Trial, Stock Soars1
24.01.Perspective Therapeutics, Inc.: Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal ...173Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding...
► Artikel lesen
PERSPECTIVE THERAPEUTICS Aktie jetzt für 0€ handeln
24.01.Perspective Therapeutics, Inc. - 8-K, Current Report-
22.01.Perspective Therapeutics, Inc.: Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET to be Presented at the ASCO Gastrointestinal Cancers Symposium on January 24, 20252
13.01.Perspective Therapeutics, Inc. - 8-K, Current Report1
06.01.Perspective Therapeutics Appoints Juan Graham As CFO4
06.01.Perspective Therapeutics names Juan Graham as finance chief3
06.01.Perspective Therapeutics, Inc.: Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer110SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
► Artikel lesen
06.01.Perspective Therapeutics, Inc. - 8-K, Current Report-
04.12.24Perspective Therapeutics, Inc. - 8-K, Current Report3
27.11.24Perspective Therapeutics-Direktor Robert Williamson erwirbt Aktien im Wert von 22.813 US-Dollar11
26.11.24Perspective Therapeutics CEO Johan Spoor kauft Aktien im Wert von 100.468 US-Dollar5
21.11.24Perspective Therapeutics, Inc.: Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-a-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society ...169[212Pb]VMT-a-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested (2.5 and 5.0 mCi)Eight of nine patients had durable control of disease....
► Artikel lesen
21.11.24Perspective Therapeutics, Inc. - 8-K, Current Report5
15.11.24Perspective Therapeutics, Inc.: Perspective Therapeutics to Discuss Data on [212Pb]VMT-a-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 20248
12.11.24Perspective Therapeutics, Inc.: Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results184Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously treated metastatic melanoma, based on preliminary results...
► Artikel lesen
12.11.24Perspective Therapeutics, Inc. - 10-Q, Quarterly Report1
12.11.24Perspective Therapeutics, Inc. - 8-K, Current Report-
11.11.24Perspective Therapeutics Q3 2024 Earnings Preview7
28.10.24Perspective Therapeutics' SWOT analysis: radiopharmaceutical stock's lead-212 edge2
Seite:  Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1